Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Merck & Co., Inc. — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.8 (market cap $2.98B), while Merck & Co., Inc. trades at $145.78 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 117.9× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and Merck & Co., Inc. pays a 2.39% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Merck & Co., Inc. for 98 Days on average.
| FNGU | MRK | |
|---|---|---|
Market Cap | $2.98B | $351.28B |
Volume | 4,682,352 | 7,969,665 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $156.43 |
52-Week Low | $13.73 | $82.49 |
Typical Hold Time | 19 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.31, down 2.39% today. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETN faces significant volatility risks, having lost 87% during previous tech sector downturns according to 247 Wallst analysis from August 19, 2026.
The outlook remains highly speculative given the leveraged structure. While bullish technicals suggest near-term upside potential to resistance at $37-39, the extreme volatility and concentration in mega-cap tech stocks present substantial downside risks during market corrections. Investors require high risk tolerance for this instrument.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
